RFX5 Back

regulatory factor X, 5 (influences HLA class II expression)

External References:      Wikipedia GeneCards HUGO COSMIC Google Scholar

NCBI Description of RFX5
A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS; MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined.

Community Annotation of RFX5 Add / Edit RFX5: Annotations

No community annotations yet for RFX5.
Sort mutations by: Tumor type  Mutation type  Position  
Straightedge cursor Expand

Figure notes


• "Mouse over" a mutation to see details.
• Missense green saturation indicates evolutionary conservation of the mutated positions.
• Red hashes in protein strip are splice sites.
• Blue-white-red bars are log2 copy ratio distributions (–1 to +1) from Zack et al. (2013).


Legend

RFX5 is highly significantly mutated in
(none)
RFX5 is significantly mutated in
(none)
RFX5 is near significance in
(none)

Click on a tumor type to see its full list of significant genes.

Data details


• Mutation list for RFX5